{{flagHref}}

Products

Products
Categories
Blog
Podcast
Application
Document

|

/ {{languageFlag}}

Inquiry

a

High dose brachytherapy with non-sealed 188Re (rhenium) resin in patients with non-melanoma skin cancers (NMSCs): single centre preliminary results.

Title	High dose brachytherapy with non-sealed 188Re (rhenium) resin in patients with non-melanoma skin cancers (NMSCs): single centre preliminary results.
Authors	Paolo Castellucci, F. Savoia, A. Farina, G. M. Lima, A. Patrizi, C. Baraldi, F. Zagni, S. Vichi, C. Pettinato, A. G. Morganti, L. Strigari, S. Fanti
Magazine	European Journal of Nuclear Medicine and Molecular Imaging
Date	11/02/2020
DOI	10.1007/s00259-020-05088-z
Introduction	High dose brachytherapy using non-sealed 188Re-resin (Rhenium-SCT®) offers a promising treatment for non-melanoma skin cancer (NMSC). This prospective study evaluated the efficacy and safety of a single application of Rhenium-SCT® in patients with NMSC. Fifty patients with 60 NMSC lesions were treated between October 2017 and January 2020. Lesions were located on the face, ears, nose, scalp, extremities, and trunk. The average lesion size was 7.0 cm², with a mean thickness of 1.1 mm. Treatment involved a mean time of 79 minutes, delivering superficial, mean, and target absorbed doses of 185 Gy, 63 Gy, and 31 Gy respectively. Follow-ups conducted at intervals up to 180 days post-treatment involved dermoscopy and biopsy. At six months, 98% of lesions showed complete response; two years post-treatment, only one lesion had relapsed. Early side effects were mild, resolving within 32 days for most cases. Cosmetic results were generally rated as excellent or good after 12 months. This treatment is a viable, non-invasive alternative when surgery or radiation therapy are not suitable. Further studies with larger populations and longer follow-ups are necessary to confirm these findings and optimise dosing.
Quote	Paolo Castellucci, F. Savoia and A. Farina et al. High dose brachytherapy with non-sealed 188Re (rhenium) resin in patients with non-melanoma skin cancers (NMSCs): single centre preliminary results. Eur. J. Nucl. Med. Mol. Imaging. 2020. Vol. 48(5):1511-1521. DOI: 10.1007/s00259-020-05088-z
Industry	Medical Devices

Related papers

Loading... Please wait...

Publish your research and articles on the SAM website

Disclaimer

This site only provides metadata for academic works to enable users to easily find relevant information. For full access to the works, please use the DOI to visit the original publisher's website. The data comes from publicly accessible scientific databases and complies with the terms of use of these platforms. If you have any concerns regarding copyright, please contact us. We will address them immediately.

Success! You are now subscribed.

You have successfully subscribed! Check your inbox soon to receive great emails from this sender.

Copyright © 1994-2025 Stanford Advanced Materials owned by Oceania International LLC, all rights reserved